semaglutide cardiovascular outcomes news today 2025 currently not cost-effective for heart patients without diabetes, study finds SELECT Trial Analysis Shows Semaglutide's
Description
The disparity in coverage between the anti-diabetic and anti-obesity GLP-1s shows how payer behavior is driven by the perceived medical necessity of products by their intended use, not by the molecule itself
While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in people with diabetes.
Its a truth as old as time: Were hardwired to crave fat and sugar
Originally designed to treat diabetes and support weight loss, GLP-1 medications...
The promise of #GLP-1 receptor agonists for #neurodegenerative diseases Dilan Athauda @DilanAthauda et al
